title: Skin testing and infliximab-specific antibodies detection as a combined strategy for preventing infusion reaction.
authors.forename: Alessandra
authors.initials: A
authors.lastname: Vultaggio
authors.forename: Andrea
authors.initials: A
authors.lastname: Matucci
authors.forename: Francesca
authors.initials: F
authors.lastname: Nencini
authors.forename: Sara
authors.initials: S
authors.lastname: Pratesi
authors.forename: Enrico
authors.initials: E
authors.lastname: Maggi
mesh_terms: D000328:Adult; D000888:Antibodies, Anti-Idiotypic / Q000276:immunology*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000009:adverse effects* / Q000276:immunology; D018501:Antirheumatic Agents / Q000008:administration & dosage / Q000009:adverse effects* / Q000276:immunology; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D001528:Behcet Syndrome / Q000188:drug therapy* / Q000276:immunology; D004342:Drug Hypersensitivity / Q000175:diagnosis* / Q000276:immunology; D005260:Female; D006801:Humans; D007073:Immunoglobulin E / Q000276:immunology*; D000069285:Infliximab; D007262:Infusions, Intravenous / Q000009:adverse effects; D008297:Male; D012882:Skin Tests
chemical_list: D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D007073:Immunoglobulin E; D000069285:Infliximab